• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cerevel Therapeutics Holdings, Inc. - Common Stock (NQ:CERE)

44.96 UNCHANGED
Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 44.96
Bid (Size) 44.97 (20)
Ask (Size) 44.98 (146)
Prev. Close 44.96
Today's Range 44.96 - 44.96
52wk Range 43.32 - 44.96
Shares Outstanding 156,832,992
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
June 03, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
June 02, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+3.6%
+3.6%

More News

Read More
CERE Deadline: Rosen Law Firm Urges Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
May 23, 2025
From Rosen Law Firm
Via Business Wire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
May 16, 2025
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE
May 11, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
May 07, 2025
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
April 29, 2025
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
April 26, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
April 25, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
April 25, 2025
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
April 21, 2025
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
April 18, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
April 18, 2025
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Robbins LLP Reminds CERE Stockholders With Large Losses to Contact the Firm for Information About the Class Action Lawsuit on Behalf of Former Cerevel Therapeutics Holdings, Inc. Shareholders
April 16, 2025
From Robbins LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
April 14, 2025
From Lowey Dannenberg, P.C.
Via GlobeNewswire
CEREVEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cerevel Therapeutics Holdings, Inc. and Encourages Investors to Contact the Firm
April 10, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Urges Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Stockholders to Contact the Firm for Information About Their Rights
April 09, 2025
From The Rosen Law Firm, P.A.
Via Business Wire
Cerevel Therapeutics Holdings, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit on Behalf of Former CERE Shareholders
April 07, 2025
From Robbins LLP
Via GlobeNewswire
Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.
April 04, 2025
From Entwistle & Cappucci LLP
Via Business Wire
Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)
March 31, 2025
From Entwistle & Cappucci LLP
Via Business Wire
CERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law Firm
February 12, 2025
From The Schall Law Firm
Via Business Wire
CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm
June 18, 2024
From The Schall Law Firm
Via Business Wire
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm
June 11, 2024
From Kaskela Law LLC
Via Business Wire
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
June 05, 2024
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
June 04, 2024
Via Benzinga

Frequently Asked Questions

Is Cerevel Therapeutics Holdings, Inc. - Common Stock publicly traded?
Yes, Cerevel Therapeutics Holdings, Inc. - Common Stock is publicly traded.
What exchange does Cerevel Therapeutics Holdings, Inc. - Common Stock trade on?
Cerevel Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cerevel Therapeutics Holdings, Inc. - Common Stock?
The ticker symbol for Cerevel Therapeutics Holdings, Inc. - Common Stock is CERE on the Nasdaq Stock Market
What is the current price of Cerevel Therapeutics Holdings, Inc. - Common Stock?
The current price of Cerevel Therapeutics Holdings, Inc. - Common Stock is 44.96
When was Cerevel Therapeutics Holdings, Inc. - Common Stock last traded?
The last trade of Cerevel Therapeutics Holdings, Inc. - Common Stock was at 07/31/24 04:15 PM ET
What is the market capitalization of Cerevel Therapeutics Holdings, Inc. - Common Stock?
The market capitalization of Cerevel Therapeutics Holdings, Inc. - Common Stock is 7.05B
How many shares of Cerevel Therapeutics Holdings, Inc. - Common Stock are outstanding?
Cerevel Therapeutics Holdings, Inc. - Common Stock has 7B shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap